Quantcast

Latest biopharmaceutical Stories

2014-05-07 08:32:47

MONROVIA, Calif., May 7, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release first quarter financial results after market close on Wednesday, May 14, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial...

2014-05-06 16:33:13

JUPITER, Fla., May 6, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today that they have strengthened their European leadership team with the addition of two senior level positions. (Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO...

2014-05-06 16:28:42

LONDON, May 6, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Cell Culture: The Market for Media, Sera and Reagents, 5th Edition http://www.reportbuyer.com/pharma_healthcare/diagnostics/cell_culture_market_media_sera_reagents_5th_edition.htmlThe growth in biopharmaceuticals is creating an unprecedented increase in demand for cell culture products. Cell culture techniques have been used in biological sciences for more than 50 years; however, cell culture...

2014-05-06 04:23:34

SEATTLE, May 6, 2014 /PRNewswire/ -- CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics'...

2014-05-05 08:27:46

SANTA ROSA, Calif., May 5, 2014 /PRNewswire/ -- Ruthigen, Inc., (NASDAQ: RTGN), a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the underwriters of Ruthigen's recently completed initial public offering have partially exercised their option to purchase additional shares of common stock. The underwriters have purchased an additional...

2014-05-05 08:27:39

Conference Call and Webcast to Follow THE WOODLANDS, Texas, May 5, 2014 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, will release its first quarter 2014 financial results on Thursday, May 8, 2014 before the financial markets open. Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for the first quarter...

2014-05-01 12:31:52

Spin-off Would Allow Cytocom to Operate as a Separate Biotechnology Company Focused on Development of LDN and MENK Immunotherapy Products ORLANDO, Fla., May 1, 2014 /PRNewswire/ -- TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or the "Company"), a biopharmaceutical company focused on the development, marketing and distribution of opioid-related immunotherapies, announced that its board of directors has approved a plan to spin off its wholly-owned subsidiary, Cytocom, Inc. ("Cytocom"), an entity...

2014-04-30 08:32:32

ATLANTA, April 30, 2014 /PRNewswire/ -- Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data sharing network PatientsLikeMe(®) presented the results of the Policy for Optimal Epilepsy Management (POEM) study at the 66(th) Annual Meeting of the American Academy of Neurology in Philadelphia, Pa. This first-time, real-world study of an online health management platform demonstrated statistically significant...

2014-04-29 23:22:06

Gallus BioPharmaceuticals, a premier pure-play biologics contract development and manufacturing organization and Omni Bio Pharmaceutical, a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT), jointly announced finalization of a multi-stage manufacturing services agreement. St. Louis, Missouri (PRWEB) April 29, 2014 Gallus BioPharmaceuticals, LLC(Gallus), a premier pure-play biologics contract development and manufacturing...

2014-04-29 08:35:33

MONROVIA, Calif., April 29, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 4:50 p.m. EDT in Boston, MA. A live audio webcast of the...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related